tiprankstipranks
Trending News
More News >
Beamtree Holdings Ltd (AU:BMT)
:BMT
Australian Market

Beamtree Holdings Ltd (BMT) AI Stock Analysis

Compare
10 Followers

Top Page

AU

Beamtree Holdings Ltd

(Sydney:BMT)

Rating:48Neutral
Price Target:
AU$0.50
▲(92.31%Upside)
Beamtree Holdings Ltd's stock score is primarily impacted by its strong revenue growth offset by significant profitability and cash flow issues. Technical analysis indicates weak market momentum, and valuation metrics reflect the current financial challenges.

Beamtree Holdings Ltd (BMT) vs. iShares MSCI Australia ETF (EWA)

Beamtree Holdings Ltd Business Overview & Revenue Model

Company DescriptionBeamtree Holdings Ltd (BMT) is a technology company that operates within the healthcare sector, providing data analytics and artificial intelligence solutions. The company's core products and services include software platforms that enhance clinical decision-making, improve data quality, and optimize healthcare management systems. By leveraging advanced analytics, Beamtree aims to deliver insights that drive better outcomes across the healthcare continuum.
How the Company Makes MoneyBeamtree Holdings Ltd generates revenue primarily through the sale of its software solutions and services to healthcare organizations. The company offers subscription-based models for its analytics platforms, which provide ongoing revenue streams. Additionally, Beamtree may engage in licensing agreements for its technology and charge consulting fees for implementing and customizing its systems to fit client needs. The company also benefits from partnerships with healthcare institutions and technology providers, which can result in collaborative projects and shared revenue opportunities.

Beamtree Holdings Ltd Financial Statement Overview

Summary
Income Statement
Balance Sheet
Cash Flow
BreakdownJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue27.60M22.77M19.09M8.39M4.12M
Gross Profit4.89M2.14M2.34M2.77M2.65M
EBITDA-331.00K-1.24M-2.28M1.02M697.11K
Net Income-5.11M-6.91M-4.45M-383.62K382.90K
Balance Sheet
Total Assets59.65M62.53M63.91M47.05M32.22M
Cash, Cash Equivalents and Short-Term Investments5.04M8.81M6.35M14.12M4.20M
Total Debt1.66M755.00K1.12M799.36K44.27K
Total Liabilities12.52M15.31M15.33M4.96M3.01M
Stockholders Equity47.14M47.22M48.58M42.09M29.22M
Cash Flow
Free Cash Flow-4.51M-1.88M-4.83M-2.64M-26.13K
Operating Cash Flow-492.00K768.00K-2.32M240.65K1.05M
Investing Cash Flow-4.02M-2.65M-5.16M-2.98M-849.49K
Financing Cash Flow749.00K4.34M-286.00K12.65M-128.49K

Beamtree Holdings Ltd Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.26
Price Trends
50DMA
0.26
Negative
100DMA
0.25
Negative
200DMA
0.26
Negative
Market Momentum
MACD
>-0.01
Positive
RSI
34.82
Neutral
STOCH
12.30
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:BMT, the sentiment is Negative. The current price of 0.26 is below the 20-day moving average (MA) of 0.29, below the 50-day MA of 0.26, and below the 200-day MA of 0.26, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 34.82 is Neutral, neither overbought nor oversold. The STOCH value of 12.30 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:BMT.

Beamtree Holdings Ltd Peers Comparison

Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
AURMD
80
Outperform
AU$57.68B28.8625.23%1.28%10.54%38.69%
AUCOH
74
Outperform
$19.32B52.2120.61%2.24%6.35%5.97%
AURHT
62
Neutral
AU$17.93M140.00-3.11%89.13%69.57%
AUMVF
52
Neutral
AU$266.90M-0.87%7.76%14.24%-109.59%
AUPYC
50
Neutral
AU$737.82M-112.97%-84.82%
48
Neutral
AU$2.43B4.28-64.25%2.90%35.15%13.63%
AUBMT
48
Neutral
AU$72.55M-11.80%14.56%13.36%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:BMT
Beamtree Holdings Ltd
0.25
0.02
8.70%
AU:COH
Cochlear
295.43
-22.24
-7.00%
AU:RHT
Resonance Health Ltd
0.04
-0.02
-33.33%
AU:PYC
PYC Therapeutics Limited
1.27
0.08
6.72%
AU:MVF
Monash IVF Group Ltd
0.68
-0.51
-42.86%
AU:RMD
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
38.95
10.61
37.44%

Beamtree Holdings Ltd Corporate Events

Beamtree Holdings Announces Cessation of Performance Rights
Jun 17, 2025

Beamtree Holdings Ltd has announced the cessation of 750,000 performance rights due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This cessation could impact the company’s capital structure and may influence stakeholders’ perceptions of the company’s ability to meet performance conditions.

The most recent analyst rating on (AU:BMT) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on Beamtree Holdings Ltd stock, see the AU:BMT Stock Forecast page.

Beamtree Holdings Announces Proposed Securities Issue
Jun 10, 2025

Beamtree Holdings Limited has announced a proposed issue of 350,000 fully paid ordinary securities, scheduled for July 1, 2025. This move is part of a placement or other type of issue, which will be quoted on the ASX, potentially impacting the company’s market presence and offering new opportunities for stakeholders.

The most recent analyst rating on (AU:BMT) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on Beamtree Holdings Ltd stock, see the AU:BMT Stock Forecast page.

Beamtree Holdings Issues New Shares in Compliance with Corporations Act
Jun 3, 2025

Beamtree Holdings Limited has announced the issuance of 375,000 fully paid ordinary shares without disclosure to investors under Part 6D.2 of the Corporations Act. This move is in compliance with relevant provisions of the Corporations Act, and there is no excluded information as per sections 708A(7) and 708A(8). This announcement reflects Beamtree’s ongoing commitment to adhering to regulatory standards while potentially enhancing its market position and stakeholder value.

The most recent analyst rating on (AU:BMT) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on Beamtree Holdings Ltd stock, see the AU:BMT Stock Forecast page.

Beamtree Holdings Limited Announces Quotation of New Securities
Jun 3, 2025

Beamtree Holdings Limited has announced the quotation of 375,000 ordinary fully paid securities on the Australian Securities Exchange (ASX) under the code BMT. This move is part of the company’s strategy to enhance its market presence and provide more liquidity to its shareholders, potentially impacting its market positioning positively.

The most recent analyst rating on (AU:BMT) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on Beamtree Holdings Ltd stock, see the AU:BMT Stock Forecast page.

Beamtree Expands into UK with NHS Confederation Partnership
May 30, 2025

Beamtree Holdings Limited has announced a strategic partnership with the NHS Confederation to expand its presence in the UK healthcare market. This collaboration aims to replicate Beamtree’s successful ANZ membership model within the NHS hospital sector in England, Wales, and Northern Ireland. The partnership will establish a benchmarking collaborative, providing NHS trusts with access to advanced analytics, benchmarking services, and peer-to-peer learning communities. The initial contract is for five years, with an option to extend, and includes a significant investment by Beamtree to establish the platform in the UK. This move is a key part of Beamtree’s growth strategy, offering potential benefits to NHS trusts through enhanced data analytics and operational benchmarking.

The most recent analyst rating on (AU:BMT) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on Beamtree Holdings Ltd stock, see the AU:BMT Stock Forecast page.

Beamtree Holdings Reports Major Q3 FY25 Progress and Strategic Wins
May 5, 2025

Beamtree Holdings Limited has announced significant progress in its operations for the third quarter of FY25, highlighted by major contract wins and strategic developments. The company has launched the Evolve Collaborative with NHS Confederation in England, renewed a contract in Ireland, and expanded its market presence in Saudi Arabia and the UK. These developments are expected to significantly increase Beamtree’s market share and annual recurring revenue, positioning the company for improved profitability and positive cash generation by the end of FY25.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 25, 2025